title: Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum.
abstract: Prostate cancer (PCa) is the most common male malignancy in many Western countries. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops to hormone-refractory tumors due to the accumulation of mutations in the androgen receptor and/or the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of prostate cancer. To date, no effective therapy is available for clinically hormone-insensitive or hormone-refractory stages of prostate cancer.
authors.affiliation: Cancer Drug Discovery Program, Migal-Galilee Technology Center, Kiryat Shmona, Israel. jamalm@migal.org.il
authors.forename: Jamal
authors.initials: J
authors.lastname: Mahajna
authors.forename: Nesly
authors.initials: N
authors.lastname: Dotan
authors.forename: Ben-Zion
authors.initials: BZ
authors.lastname: Zaidman
authors.forename: Roumyana D
authors.initials: RD
authors.lastname: Petrova
authors.forename: Solomon P
authors.initials: SP
authors.lastname: Wasser
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011944:Receptors, Androgen / Q000378:metabolism; D020940:Reishi / Q000737:chemistry*; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents; D011944:Receptors, Androgen